Tumor angiogenesis: Tutorial on implications for imaging

Radiology

Volumn 203, Issue 3, 1997, Pages 593-600

  Passe, Theodore J ^a   Bluemke, David A ^a   Siegelman, Stanley S ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Blood vessels, MR; Neoplasms, blood supply; Neoplasms, metastases; State of art reviews

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANTIBODY; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GADOLINIUM PENTETATE; MEDROXYPROGESTERONE; METALLOPROTEINASE INHIBITOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PACLITAXEL; PENTOSAN POLYSULFATE; SOMATOSTATIN; SURAMIN; TECOGALAN; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DOPPLER FLOWMETRY; HUMAN; METASTASIS; MICROVASCULATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0030978336     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.203.3.9169673     Document Type: Review

References (82)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Gasparini G, Harris A. Clincal importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool: review. J Clin Oncol 1995; 13:765-782.
3. Battegay E. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995; 73:333-346.
4. Ziche M, Morbidelli L, Donnini S. Angiogenesis. Exp Nephrol 1996; 4:1-14.
5. Denekamp J, Hobson B. Endothelial cell proliferation in experimental tumors. Br J Cancer 1982; 46:711-720.
6. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1992; 66:181-196.
7. Berkowitz B, Wilson C. Quantitative mapping of ocular oxygenation using magnetic resonance imaging. Magn Reson Med 1995; 33:579-581.
8. Mclaren J, Prentice A, Charnockjones D, Smith S. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996; 11:220-223.
9. Arbiser J. Angiogenesis and the skin: a primer. J Am Acad Dermatol 1996; 34:486-487.
10. O'Brien E, Garvin M, Dev R, et al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994; 145:883-894.
11. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992a; 3:65-71.
12. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-1763.
13. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267:10931-10934.
14. Knighton D, Hunt T, Scheuenstuhl H, Halliday B, Werb Z, Kozai Y. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 1983; 221:1283-1285.
15. Dameron K, Volpert O, Tainsky M, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin 1. Science 1994; 265:1582-1584.
16. Dvorak H, Senger D, Dvorak A. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983; 2:41-73.
17. Cockerill G, Gamble J, Vadas M. Angiogenesis: models and modulators. Int Rev Cytol 1995; 159:113-160.
18. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996; 2:167-168.
19. Dipietro L. Wound healing: the role of the macrophage and other immune cells. Shock 1995; 4:233-240.
20. Lewis C, Leek R, Harris A, McGee J. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol 1995; 57:747-751.
21. Sunderkotter C, Goebeler M, Schulze-Osthoff K, Bhardwaj R, Sorg C. Macrophage-derived angiogenesis factors. Pharmacol Ther 1991; 51:195-216.
22. Thorgeirsson U, Lindsay C, Cottam D, Gomez D. Tumor invasion, proteolysis, and angiogenesis. J Neurooncol 1994; 18:89-103.
23. Polverini P. The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 1995; 6:230-247.
24. Weidner N, Semple J, Welch W, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8.
25. Leek R, Harris A, Lewis C. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol 1994; 56: 423-435.
26. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993; 10:302-313.
27. Weinstat-Saslaw D, Steeg P. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 1994; 8:401-407.
28. Liotta L, Kleinerman J, Saidel G. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer 1974; 34:997-1004.
29. Liotta L, Saidel G, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976; 36:889-894.
30. Weidner N. Intratumor microvessel density as a prognostic factor in cancer (comment). Am J Pathol 1995; 147:9-19.
31. Dvorak H, Brown L, Detmar M, Dvorak A. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029-1039.
32. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi B. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994; 5:89-97.
33. Senger D, Brown L, Claffey K, Dvorak H. Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis 1995; 14:385-394.
34. Esch F, Baird A, Ling N, et al. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci USA 1985; 82:6507-6511.
35. Asahara T, Bauters C, Zheng L, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92:5365-5371.
36. Harris A, Fox S, Bicknell R, et al. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer 1994; 74:1021-1025.
37. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348:555-557.
38. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69:212-216.
39. Bicknell R. Vascular targeting and the inhibition of angiogenesis. Ann Oncol 1994; 5:S45-S50.
40. Hawkins MJ. Clinical trials of antiangiogenic agents. Curr Opin Oncol 1995; 7:90-93.
41. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987; 104: 689-696.
42. Sidky Y, Borden E. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer Res 1987; 4:5155-5161.
43. Brem H, Folkman J. Analysis of experimental antiangiogenic therapy. J Pediatr Surg 1993; 28:445-450.
44. Schweigerer L, Fotsis T. Angiogenesis and angiogenesis inhibitors in paediatric diseases. Fur J Pediatr 1991; 151:472-476.
45. White C, Sondheimer H, Crouch E, Wilson H, Fan L. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197-1200.
46. Myers C, Cooper M, Stein C, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992; 10:881-889.
47. Slavin J. The role of cytokines in wound healing. J Pathol 1996; 178:5-10.
48. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972; 48:347-356.
49. Li V, Folkerth R, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994; 344:82-86.
50. Meyer G, Yu E, Siegal J, Petteway J, Blumenstein B, Brawer M. Serum basic fibroblast growth factor in men with and without prostate cancer. Cancer 1995; 76:2304-2311.
51. Nguyen M, Watanabe H, Budson A, Richie J, Hayes D, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86:356-361.
52. O'Reilly M, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell 1994; 79:315-328.
53. O'Reilly M, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2:689-692.
54. Axelsson K, Ljung B, Moore D, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995; 87:997-1008.
55. Horak E, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340:1120-1124.
56. Horak E, Harris A, Stuart N, Bicknell R. Angiogenesis in breast cancer: regulation, prognostic aspects, and implications for novel treatment strategies. Ann N Y Acad Sci 1993; 698:71-84.
57. Wang J, Kumar S, Pye D, van Agthoven A, Krupinski J, Hunter R. A monoclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues. Int J Cancer 1993; 54:363-370.
58. Wang J, Kumar S, Pye D, Haboubi N, AlNakib L. Breast carcinoma: comparative study of tumor vasculature using two endothelial-cell markers. J Natl Cancer Inst 1994; 86:386-388.
59. Visscher D, Smilanetz S, Drozdowicz S, Wykes S. Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal Quant Cytol Histol 1993; 15:88-92.
60. Visscher D, Lawrence W, Boman S. Angiogenesis in breast carcinoma: clinico-pathologic relevance and potential use as a quantifiable surrogate endpoint biomarker. J Cell Biochem Suppl 1994; 19 (suppl):146-152.
61. Barbareschi M, Gasparini G, Morelli L, Forti S, Dalla Palma P. Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res Treat 1995; 36:181-192.
62. Srivastava A, Laidler P, Davies R, Horgan K, Hughes L. The prognostic significance of tumor vascularity in intermediate thickness (0.76-4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol 1988; 133:419-423.
63. Gagliardi A, Collins D. Inhibition of angiogenesis by anti-estrogens. Cancer Res 1993; 53:533-535.
64. Haran E, Maretzek A, Goldberg I, Horowitz A, Degani H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelial growth. Cancer Res 1994; 54:5511-5514.
65. Bhujwalla Z, Glockner J, Artemov D, Glickson J. Magnetic resonance imaging of tumour vascular volume and permeability of metastatic human breast cancer and non-metastastic rodent fibrosarcoma lines (abstr). In: Proceedings of the Fourth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 1996; 348.
66. Abramovitch R, Meir G, Neeman M. Neovascularization induced growth of implanted C6 glioma multicellular spheroids: magnetic resonance microimaging. Cancer Res 1995; 55:1956-1962.
67. Ogawa S, Lee TM, Kay A, Tank D. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A 1990; 87:9868-9872.
68. Vandijke C, Brasch R, Roberts T, et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 1996; 198:813-818.
69. Castillo M, Kwock L, Mukherji S. Clinical applications of proton MR spectroscopy. AJNR 1996; 17:1-15.
70. Kaplan O, Cohen J. Metabolism of breast cancer cells as revealed by non-invasive magnetic resonance spectroscopy studies. Breast Cancer Res Treat 1994; 31:285-299.
71. Weinreb J, Newstead G. MR imaging of the breast. Radiology 1995; 196:593-610.
72. Lee W, Chu J, Houng S, Chung M, Wang S, Chen K. Breast cancer angiogenesis: a quantitative morphologic and Doppler imaging study. Ann Surg Oncol 1995; 2:246-251.
73. Villena-Heinsen C, Ertan A, Tossounidis I, Hollander M, Konig J, Schmidt W. Diagnostic value of color Doppler ultrasound in breast tumors. Geburtshilfe und Frauenheilkunde 1995; 55:541-547.
74. Kutschker C, Allgayer B, Hauck W. Evaluating the morphology of uncertain breast tumors using color coded Doppler ultrasound (abstr). Ultraschall in der Medizin 1996; 17:18-22.
75. Orel S, Schnall M, LiVolsi V, Troupin R. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 1994; 190:485-493.
76. Hulka C, Smith B, Sgroi D, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995; 197:33-38.
77. Buadu L, Murakami J, Murayama S, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996; 200: 639-649.
78. Frouge C, Guinebretiere J, Contesso G, DiPaola R, Blery M. Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. Invest Radiol 1994; 29:1043-1049.
79. Scopinaro F, Schillaci O, Scarpini M, et al. Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994; 21:984-987.
80. Osborne A, ed. Diagnostic neuroradiology. St Louis, Mo: Mosby-Year Book, 1994; 537, 541.
81. Newman J, Bree R, Rubin J. Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology 1995; 195:86-90.
82. Degani H, Furman E, Fields S. Magnetic resonance imaging and spectroscopy of MCF7 human breast cancer: pathophysiology and monitoring of treatment. Clin Chim Acta 1994; 228:19-33.